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It is generally agreed that the object of surgery is notachieved without complete removal of all pulmonary
metastatic tumor. In current practice, pulmonary metasta-
sectomy may be performed more than once so conservative
resections are recommended. Preservation of as much
functioning lung parenchyma is an agreed principle while
removing a centimetre of the surrounding pulmonary tissue.
For nodules located peripherally, stapled wedge resection is
generally the preferred treatment but for large or central
lesions, segmental resections, lobectomy, or occasionally,
pneumonectomy may be required. Other techniques have
been proposed as an alternative, both to save as much sur-
rounding lung as possible and reduce trauma to patients with
a low cardiopulmonary reserve. The following techniques are
described in this literature:




5. Saline enhanced thermal sealing system
6. Image—guided ablative therapies
7. Stereotactic radiosurgery (CyberKnife)
CAUTERY RESECTION (PRECISION RESECTION)
This type of resection has been proposed to reduce the
amount of parenchymal resection in patients with multiple
lesions (metastases) or in patients who are not considered
good candidates for segmentectomy or lobectomy. Deep-
seated lesions or nodules located on the broad surface of the
lung may be excised by coring them out of the parenchyma
using cautery. This method was initially described by Perel-
man1 and subsequently proposed with Cooper et al.2; it
consists of painstakingly slow coagulation of the surrounding
lung parenchyma with individual ligation of small vessels and
bronchi in the depth of the resultant cavity.
When the precision cautery dissection technique is
used, the lung must be inflated. If deep seated lesions are to
be excised, the procedure is begun on the surface of the lobe
nearest to the lesion. The electrocauthery is used to outline a
circle on the pleural surface corresponding to the size of the
core of lung to be excised. Using fine-tipped cautery forceps,
very small bites of tissue are coagulated and incised with
scissors. Thus, the lung tissue to be excised is separated from
the surrounding lung without bleeding or major leakage of
anesthetic gas. Blood vessels or bronchi are isolated and
divided between ligatures. This technique is not ideally suit-
able for the video-assisted thoracoscopic surgery approach
since it requires the lung to be in an inflated state. Electro-
cautery on a high setting generates smoke, charred tissue
sticks to the electrode, and moderate sized blood vessels
bleeding before coagulating. It is difficult to cope with these
thoracoscopically.
LASER RESECTION
Laser has three major advantages: it permits limited
excision of deep-seated lesions sparing lung tissue as much as
possible; there is minimal deformity or damage to the adja-
cent lung tissue; for lesions located near a major bronchus or
vessel a maximum margin of tissue around the lesion can be
taken without injury to these adjacent structures. The major
disadvantage is that the technique is tedious and time con-
suming.2 In 1985, LoCicero et al.5,6 reopened the debate on
the use of lasers in open thoracic surgery. His initial research
was performed with a CO2 laser; however, this is a pure
absorption or cutting laser and is inadequate for lung surgery.
As a result, a number of centers in the United States, Japan,
and Europe began experimenting with 1064 nm Nd:YAG
lasers, using bare fibers and sapphire tips to perform super-
ficial resections but failed with central tumors.7–12
On the basis of that initial experience, further research
on laser devices and wavelengths have been promoted to
improve results. The lung parenchyma has a typical water
content of 80% but a very low tissue density (only one-fifth
of the liver parenchyma), a very low heat capacity, and
variable air content and is an ideal organ for photothermal
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laser applications. Giving the high vessel density, resecting
lung parenchyma requires laser wavelengths with powerful
coagulation capability and excellent cutting properties to
prevent bleeding and prolonged air leakage. For these rea-
sons, the 1318-nm laser is the only one to be considered to
work on the lung parenchyma; this is due to its 10 times
higher absorption of water, with a still sufficient laser light
scatter related to its proximity to the beginning infrared
spectrum, able to satisfy the vital coagulation requirements.7
The disadvantage of this promising wavelength was related to
the difficulty in developing a laser device able to deliver a
satisfactory power output. The only laser device able to
produce this wavelength in the 1980s was the Nd:YAG laser
delivering 25 Watt power output on a second wavelength
level; this was sufficient to start with clinical application. Ten
years later, in 1996, a Nd:YAG laser system has been devel-
oped delivering a power output of 40 Watts; this improve-
ment was obtained by increasing the system’s efficiency to a
maximum but the main disadvantage, that is a time consum-
ing resection process remained. Finally, in 2007, due to
nanotechnology a pure high power diode laser was devel-
oped; this device is now able to deliver 100 Watts of the 1318
nm wavelength. This laser device, configured as a bare fiber
on a handpiece, delivers power densities of 80 kW/cm2 at
tissue level, reducing the resection time to one-third. Thirty
metastases in one lung ranging between 1 and 2 cm (60%
peripheral–40% central) can now be resected in an hour. The
benefit of the improvement for the patient is a significant
reduction of postoperative photo thermal edema of lung tissue
due to the lower heat exposure time.
Laser metastasectomy is usually performed through a
muscle sparing anterolateral thoracotomy (staged 3–4 weeks
for bilateral lesions) after fulfilling the standard indication
criteria for pulmonary metastasectomy. All visible and pal-
pable nodules are noted; in the collapsed lung the nodules are
dissected from the residual lung by the most direct route with
2 to 3 mm tumor margins (plus a 5-mm rim of residual lung
necrosis secondary to laser energy dispersal). In comparison
with electrocautery, ultrasonic or ligasure incisions the
1318-nm noncontact laser resection can be performed from
the periphery up to the center of a lobe without bleeding. In
this way metastases up to diameters of 8 cm can be resected;
up to 100 metastases per lung have been removed.13 Within
one-thousandth of a second, heat dissipation reaches the
volume of 20 to 30 alveoli triggering their shrinking. The
interstitial space, capillaries, small lymphatic and blood ves-
sels are closed avoiding tumor cell spread. Exposed bronchial
branches at the segmental level are usually over sewn with
absorbable suture and the segmental vessels are ligated. The
lung architecture and orientation is reconstructed after each
nodular resection by reapproximating the visceral pleura with
a running absorbable suture. This technique avoids distortion
of the lung tissue.
The group that has dedicated more efforts to the devel-
opment of this technique is the one of Rolle et al.14 In their
initial experience with the first 100 patients, overall survival
for complete curative resection was 82% at 1 year, 66% at 3
years, and 30% at 5 years. In 2006, this group published the
results on 328 patients with a 5-year survival of 41% follow-
ing laser resection of a mean of eight metastases per patient
(range 1–124).15 They recommended laser resection of 20
metastases and more because a 5-year survival of 26% was
observed.
The new 1318-nm laser demonstrates a significant
influence on parenchyma sparing during metastasectomy and
seems to minimize complications; it may expand the indica-
tions for surgical treatment for pulmonary metastases; allow-
ing more complete resection; patients at present not consid-
ered ideal candidates because of poor residual lung function
or multifocal pulmonary disease may be included in the
future. The disadvantages of a laser system are the initial
financial investment, staff education and training in security
and handling of this special technology, the additional need
of a high performance evacuation system and other unpleas-
ant things like wearing goggles.
USE OF THE LIGASURE SYSTEM
The LigaSure Vessel Sealing-System16–19 is an electro-
thermal bipolar tissues sealing system proposed for nonana-
tomic staplerless pulmonary resection. The LigaSure Vessel
Sealing-System allows local hemostasis by vessel compres-
sion and obliteration through the emission of a bipolar energy
determining the fusion of collagen and elastin in vessel walls
and subsequent tissue reformation with creation of a perma-
nent seal zone. The system automatically detects the thick-
ness of tissue to be coagulated defining the amount of energy
required to minimize the effect on surrounding tissue (1.0
mm–1.5 mm). The vessel and airways sealing capabilities of
the LigaSure system have been assessed detecting the burst
pressure for each anatomic structure using a pig lung model19
indicating it is effective for vessels less than 7 mm in
diameter but for bronchi only up to 4 mm.
The experience with LigaSure System is limited in
thoracic surgery. Clinical series18,19 totaling 84 wedge resec-
tions in 36 patients, through video-assisted thoracoscopic
surgery and thoracotomy indicate it is effective. Surgical
parameters (operating time, bleeding, intrapostoperative com-
plications; postoperative drainage stay, hospitalization) are
similar to those observed using staplers and it allows better
tailoring of resection margins with minimal thermal damage.
With a thoracoscopic approach, the Ligasure system avoids
the difficulty encountered in manipulating the stapler within
the thoracic cavity and avoids the use of multiple reloadable
cartridges, thus reducing the costs of disposable surgical
supplies.
The major disadvantages encountered using this system
are the longer operative time required to perform the resec-
tion of deeply located pulmonary lesions and the impossibil-
ity of safety excising lesions near the hilum or the great
vessels.
ULTRACISION SCALPEL (HARMONIC SCALPEL)
Ultracision works by liberating energy at the tip of the
instrument as an ultrasonic wave with a frequency of 55.5
kHz. The longitudinal waves coagulate by denaturing pro-
teins. Tissue is separated by forming steam bubbles with a
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temperature not exceeding 100°C. Further advantages include
reduced lateral spreading of heat, which allows operating
near vulnerable structures, and minimal smoke production.
The velocity of tissue separation can be controlled very well
by variation of manual pressure. The coagulative and cauter-
ing effect on tissue has been verified clinically by the excel-
lent control of bleeding,20 and histologic examination of the
resected lung tissue20–23 in lung parenchyma of animals and
humans.
SALINE-ENHANCED THERMAL SEALING
It was recently shown that the familiar diathermy with
a continuous flow of electrically conductive saline between
the tissue and the diathermy electrode results in marked
changes in the coagulative property of the diathermy on
living tissue. Two new devices, a monopolar floating ball
device and a bipolar sealing forceps, provide a continuous
flow of electrically conductive saline to the interface between
a metal electrode and tissue. The saline couples radiofre-
quency electrical energy into tissue in which it is converted
into thermal energy. The flow of saline provides cooling to
limit peak tissue temperatures to 100°C or less. This is
different from other conventional electrosurgical devices in
which tissue temperature can easily exceed 300°C, resulting
in tissue desiccation, char formation, smoke generation, elec-
trodes sticking to tissue, and undesired lateral thermal dam-
age. The new technology avoids these undesirable tissue
effects, while producing the levels of tissue temperature
required to achieve both hemostasis and pneumostasis of lung
tissue. These two devices have been used to perform both
nodulectomies (floating ball) and wedge resections (bipolar
sealing forceps).30 The resected specimens were carefully
examined to assess thermal injury at the margins; the thermal
spread averaged 2.5 mm (range 2.2–3.6 mm), and there was
no difference in the depth of coagulative necrosis between the
floating ball device and the sealing forceps. The surgeon
needs to individually divide the coagulated vessel and bron-
chiole and more time is needed compared with the conven-
tional electrocauthery or laser procedures. Also, as the oper-
ated lung is deflated, there is a tendency to remove more
functional lung tissue than would be necessary or desirable.
This drawback can be overcome by experience. Pathologic
interpretation of the resection margin is not a concern since
the depth of the coagulative necrosis caused by thermal
spread averaged only slightly more than 2 mm. This com-
pares favorably with the conventional technique using sta-
plers, which must be removed before cutting microscope




Less invasive therapies have been proposed. There is a
question though about whether they accomplish complete
eradication. The margins are not amenable to histologic
proof. Their attraction is that they do not required general
anesthesia.






Percutaneous thermal tissue ablation is performed
with electrodes inserted into the lesion under imaging
guidance; the tip has a non-insulated portion that generates
medium frequency electromagnetic waves of 400 –500
kHz. Adhesive grounding pads are applied to the thighs or
back. The insertion technique is similar to a routine per-
cutaneous biopsy. The mechanism of tissue heating for
radiofrequency ablation is frictional or resistive energy
loss caused by the motion generated by the ionic current.
Alternating radiofrequency current agitates ions in the tissue
surrounding the needle creating frictional heat, which dena-
tures and destroys tissue at predictable temperatures, in a
relatively predictable volume.
The electrode is inserted directly into the tumor with
the use of ultrasound for chest wall and pleural based masses;
computed tomography (CT) or magnetic resonance are used
for lesions located deep in the lung parenchyma.
Lung tumors seem to be good targets for radiofre-
quency ablation because the surrounding air in the adjacent
normal lung parenchyma provides an insulating effect, thus
concentrating the energy within the tumor.33 As a result, less
radiofrequency energy deposition is required to achieve ad-
equate tumor heating than with intrahepatic pathology. Con-
versely, if there is a large vessel nearby heat is conducted
away. Interest in this procedure in the treatment of lung
neoplasms is demonstrated by the increasing number of
reports published.35– 42 There is heterogeneity in these
studies, including various approaches (percutaneous or
open), type of device, patient characteristics and duration of
follow-up.
It is reported to be low risk and well tolerated but the
most frequent complication, pneumothorax, occurs in up to
43% of the patients35 when the transcutaneous approach is
used. Other reported complications were intraprocedural
pain, hemorrhage, hemoptysis, persisting air leaks, acute
respiratory distress syndrome, reactive pleural effusions,
damage to the adjacent anatomic structures, skin burns, and
infections or abscess formation. The authors agree that le-
sions larger than 3.5 cm are difficult to destroy.43 There are
currently three commercially available systems. Of these
systems, two (Radio-therapeutics, Boston Scientific and
RITA Medical Systems, Inc) use a deployable array electrode
that consists of 10–16 small wires deployed through a 15–17
gauge needle. The third system (Valleylab, Inc, Boulder, CO)
uses a single or triple cluster perfused electrode. This inter-
nally cooled electrode can increase the volume of the induced
thermocoagulation by between 4 and 7 cm in diameter, as
reported in the liver,44 but it may be greater in the lung due
to the insulative effect of aerated tissue.
Objective results are more difficult to assess. Imaging
techniques such as contrast – enhanced CT or positron emission
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tomography have been used to determine the therapeutic re-
sponse and to plan further treatment.36,40,45,46 Gadalata et al.47 in
2004 reporting on 63 primary or metastatic lung cancers with
percutaneous CT-guided radiofrequency ablation claimed a
complete tumor necrosis response rate in 92% with a mean
follow up period of 9 months. Steinke et al.35 reported on 23
patients with 52 colorectal pulmonary metastases treated with
radiofrequency ablation; 10/23 had a pneumothorax (43%),
and five patients died of diffuse metastatic disease in the first
year after the intervention (22%). Short-term local control
rates metastatic lung tumors less than or equal to 3 cm have
been shown by multiple investigators; however, studies with
longer term control rates are necessary.
Microwave Ablation
Microwave ablation refers to the use of all electromag-
netic methods for inducing tumor thermocoagulation using
devices with frequencies more than or equal to 900 MHz.48,49
This technique is similar to radiofrequency ablation, because
it is a heat-based tumor ablation method. As with radiofre-
quency ablation, microwave ablation may be performed ei-
ther percutaneously (under either conscious sedation or gen-
eral anesthesia) or through open surgical approach. CT
guidance is the most widely used approach.
Unlike radiofrequency ablation, microwave ablation
induces thermocoagulation via an electromagnetic wave,
which causes marked oscillation of water molecules in the
tissue surrounding the active tip.50 Because of the inherent
properties of the electromagnetic wave (no electrical current
being produced) the device doesn’t need to be grounded,
avoiding the risk of grounding pad burns. Intratumoral tem-
peratures can be accurately measured by the separate place-
ment of a thermocouple adjacent to the active antenna. Given
the poor electrical conduction of air, microwave energy may
provide better heating around soft tissue nodules as compared
with radiofrequency energy, although this has not been sci-
entifically proven yet.
Microwave ablation offers many of the benefits of
radiofrequency ablation but has several advantages that may
result in an improved tumor thermocoagulation, with greater
energy deposition in the aereated lung and greater heating
near the blood vessels.50 During radiofrequency ablation the
zone of active tissue heating is limited to a few millimeters
surrounding the active electrode, with the remainder of the
ablation zone being heated via thermal conduction. Owing to
the broader field of power density deposition, microwave
ablation results in a much larger zone of active heating.52 This
has the potential to allow for a more uniform tumor kill in the
ablation zone, both within the target zone and next to blood
vessels. Radio frequency ablation is limited by the increase in
impedence with tissue boiling and charring,53 since water
vapor and char act as electrical insulators. Because of their
electromagnetic nature, microwave ablations are not subject
to this limitation, with an intratumoral temperature consider-
ably higher and a larger ablation zone with a shorter ablation
period.
Indications are still limited and use should be restricted
to local control. In patients with metastatic disease not ame-
nable to surgery either for concurrent contraindications or
because the patient refused it this type of treatment could be
indicated.
Cryoablation Technique
Cryoablation technique (also known as cryotherapy)
can be performed with an argon-based Cryoablation system
(Endocare, Irvine, CA). The patient undergoes a 10 minutes
freeze followed by 8 minutes active helium thaw followed by
another 10 minutes freeze. The number of freeze-thaw-freeze
cycles remains dependent on the individual clinical case. A
post treatment CT scan is usually performed with the low
density changes within the target measured and approximated
to the size of the ablated region. Because the margin of the
cytotoxic temperatures may not have been achieved, a 1-cm
margin is subtracted from the diameter of the low density
ablated region to better approximate the true volume of the
necrosis.54
Cryotherapy exerts its ablative effects via a number
of tumoricidal pathways, including direct cytolysis via
intra and extracellular ice crystal formation causing protein
denaturation, intracellular dehydration and pH changes, isch-
emic necrosis via vascular injury, cellular edema and vessel
disruption during the thaw phase, activation of antitumor
immune responses, and induction of cellular apoptosis.
Endothelial damage leads to platelet aggregation and
microthrombosis.43
A frequently mentioned benefit of cryoablation over
other heat-based ablative techniques is the apparent ability to
preserve collagenous and other structural cellular architecture
in frozen tissues.43 Another potential benefit would include
the ability to visualize lower attenuation ice as it covers a soft
tissue mass during the freeze cycles.
The use of this technique within the respiratory system
has been widely popularized through the rigid bronchoscope
in the treatment of endobronchial neoplasms.55 With the
development of newer argon-based cryoablation systems,
cryotherapy applicator diameters have significantly de-
creased, making percutaneous utilization feasible. Recently,
it has also been proposed to ablate lung tumors55: Wang
reported on 217 sessions in 187 patients with lung cancer.
The short follow-up does not allow estimates of survival but
quality of life increased significantly.
STEREOTACTIC RADIOSURGERY FOR LUNG
TUMORS (CyberKnife)
The most frequently used system for stereotactic radio-
surgery is the CyberKnife System (Accuracy Inc, Sunnyvale,
CA). It involves a 6-MV x-band linear accelerator mounted
on a computer-controlled robotic arm. The means of targeting
is based on two ceiling-mounted diagnostic x-ray sources
with table-mounted flat-panel detectors.58 For precise image
localization, percutaneously placed metal marker (fiducials)
are inserted in, or adjacent to the tumor. This maneuver is
usually accomplished using an 18- or 19-gauge needle under
CT guidance and local anesthesia; 2 to 4 cylindrical gold
metal fiducials (1 mm in diameter by 3 mm in length) are
inserted. A radiation therapy immobilization device is custom
made for each patient to minimize non respiratory motion
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during treatment. Patients undergo contrast-enhanced CT
scan of the chest and a radiosurgical treatment plan is devel-
oped using a nonisocentric, inverse-planning algorithm based
on tumor geometry and location. The tumor is outlined in
sequential axial CT images and the gross tumor volume is
calculated. Adjacent structures within 5 cm of distance are
identified to avoid incidental radiation. The radiation to be
delivered is prescribed to the maximum isodose line that
completely covers the gross tumor volume, and the imaging
set is processed for radiosurgery. The system coordinates the
radiation treatment plan with the mechanical delivery therapy
by dividing the dose into approximately 100 beam directions
(called nodes).
The problem of tumor motion due to respiration may be
addressed either by a breath holding technique or by tracking
light emitting diodes placed on the patient’s skin. The move-
ments of the light emitting diodes are correlated with tumor
movements using a ceiling-mounted light detector; the ro-
botic arm and linear accelerator are able to track respiratory
motion of the tumor.59
Treatment planning is usually done with a proprietary
system allowing inverse planning and nonisocentric radiation
delivery. After determining the total radiation dose to be
delivered to the tumor and defining the boundaries to protect
the adjacent critical structures, the software determines the
targeting positions and dose to be delivered from the targeting
positions. Radiation is then delivered for a calculated period
of time from specific orientations and directions, each of
which is called a node. The current CyberKnife device allows
for up to 12 different beam directions from up to 110 robot
arm locations, for a total of 1320 possible beam paths.
The greatest limitation to a more widespread use of this
technique is the low overall efficacy when compared with
surgical resection (notwithstanding the fascinating term “ra-
diosurgery”). In fact, a complete radiologic response (that
does not correspond to an histologically proven complete
response) has been reported in only 9% of the patients with
lung tumors and partial response in 65% of them.60 Addi-
tional studies are under design and evaluation to investigate
the optimal radiation dose, best motion-compensation tech-
nique, and overall treatment efficacy.
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